Date: 2017-01-23
Type of information: Nomination
Compound:
Company: Kymab (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 23, 2017, Kymab announced the appointment of Dr Arndt Schottelius as its first Executive Vice President Research & Development. Dr Schottelius will lead the Research and Development activities, including pre-clinical and clinical developments of Kymab’s expanding therapeutic antibody portfolio. The appointment will take effect in May 2017.
Dr Schottelius joins Kymab from MorphoSys , where he served as the first Chief Development Officer since 2008, developing the portfolio of proprietary therapeutic antibody programmes in cancer and immunology. Prior to his role at MorphoSys, Dr Schottelius was a Medical Director, Immunology Development at Genentech, where he directed early and late-stage clinical development programmes of therapeutic antibodies. Before joining Genentech, Dr Schottelius held science and management positions in immunology research at Schering AG, and Berlex Biosciences.
Financial terms:
Latest news:
Is general: Yes
